Hangzhou Conlead Pharmaceutical has grandly opened, creating a high-end pediatric formulation research and development base!

In September 2023, Hangzhou Conlead Pharmaceutical Technology Co., Ltd. grandly opened! Conlead pharmaceutical is a pharmaceutical research and development enterprise jointly established by Leadingpharm Pharmaceuticals and Huluwa Pharmaceutical. With high-end pediatric formulation research and development as the core, it has built formulation platforms such as oral dissolution films, complex particles, and special oral solutions, covering pharmaceutical research, in vitro and in vivo evaluations, and registration applications in the fields of chemical medicine, traditional Chinese medicine, and biopharmaceuticals. It can provide high-quality and efficient research and development services for domestic and foreign pharmaceutical enterprises. The establishment of Conlead Pharmaceutical has filled the gap in the high-end pediatric drug research and development field in Hangzhou, injecting new vitality into the Hangzhou pharmaceutical industry cluster as a global pharmaceutical research and development highland!
 

At the opening ceremony, Ms. Julie Gao, President of Leadingpharm and General Manager of Conlead, first warmly welcomed the leaders and experts who attended the ceremony, and expressed deep gratitude to the government leaders at all levels of Hangzhou Xiaoshan District Airport Economic Demonstration Zone and relevant leaders of Jihua Industrial Park for their strong support. Ms. Julie Gao stated that Leadingpharm and Huluwa share the same philosophy and vision. The integration of both sides will fully leverage Huluwa's rich layout of pediatric medication products, efficient and sustainable production and sales system, Leadingpharm’s CXO Whole Industry Chain Layout, and deep research and development accumulation, unleashing super vitality.
 

Ms. Gao stated that Conlead will shoulder the responsibility of safeguarding children's health, meet unmet clinical needs, carry out pediatric drug research and development in an innovative way, with passion and courage to break through. Together with industry experts and upstream and downstream partners in the industry chain, we will work together to seek development, consolidate innovation and win the future, become the engine of pediatric drug research and development in the Yangtze River Delta region, and help Hangzhou become a global pharmaceutical research and development highland!
 

Mr. Guo Rong, Deputy Director of the Hangzhou Airport Economic Demonstration Zone Management Committee, warmly congratulated Conlead on its opening. He emphasized the importance of close cooperation between the management committee and Conlead, hoping that both sides can grow together, face challenges directly, and share future development achievements. Director Guo stated that the management committee and the park will fully support the development of Conlead, strive to create a good business environment, help Conlead achieve more innovative results, and contribute to the development of Chinese pediatric medicine.
 

Mr. Luo Jianchao, a director of Taloph Pharmaceutical (parent company of Leadingpharm), stated in his speech that currently, there are still problems in the field of children's medication in China, such as insufficient variety and insufficient dosage forms. He hopes that Conlead Pharmaceutical can leverage the policy of encouraging children's drug research and development in China, fully leverage the advantages of Leadingpharm Group and Huluwa, develop more efficient and safe children's medication, meet market and clinical needs, and work together to contribute to the cause of children's health in China!
 

Ms. Liu Jingping, Secretary of the Party Committee and Chairman of Huluwa, and Chairman of Hangzhou Conlead, first thanked the entire team for their efforts in opening Conlead in her speech. Ms. Liu stated that the development, production, and sales of children's drugs are all very difficult tasks, but there are nearly 300 million children in China, and we need to safeguard their health. Huluwa has always been committed to building a national brand of Chinese pediatric medicine and striving to create social value. The completion and opening of Conlead is a practice of technological innovation and industrial integration. In the future, Conlead will continue to deepen its efforts in technological innovation, digital economy building, brand communication, and internationalization. We believe that with the support of all leaders and experts, through the strong alliance of Leadingpharm and Huluwa, as well as the joint efforts of the R&D team, Conlead will definitely bear fruitful results on the land of Hangzhou!